New drug combination brings 1-2 punch against acute leukemia

Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation.

In a preclinical study, Lauren Akers, D.O., postdoctoral fellow from the Children's Cancer Hospital at M. D. Anderson, found that combining a novel glycolysis inhibitor, 3-BrOP, with mTOR inhibitor, rapamycin, induced more than 90 percent cell death in human tissue cultures of acute lymphocytic leukemia. She presented her study at the American Society of Pediatric Hematology/Oncology annual conference on May 16.

"We already knew that 3-BrOP was effective in preclinical research of glioblastoma, colon cancer and lymphoma, and most recently acute leukemias" says Akers, lead investigator on the study. "We also knew that mTOR inhibitors intensify cellular starvation. This study showed that the two together have a more powerful impact on treating acute lymphocytic leukemia, which is the most common childhood cancer."

Glycolysis is a process that turns glucose into energy for cells. Unlike healthy cells that get their energy for growth from both glycolysis and respiration, cancer cells are highly dependent on glycolysis. Using the M. D. Anderson-developed drug, 3-BrOP, researchers inhibited glycolysis, thus starving the leukemia cells from their energy source while leaving healthy cells free to get their energy from respiration.

Rapamycin is an mTOR inhibitor that keeps cancer cells from coping with stress, thus resulting in cell death. When researchers on the study combined the two drugs, they discovered a synergistic effect.

"We found that a lower dosage of 3-BrOP with rapamycin created the same results of more than 90 percent tumor cell death," says Akers. "Theoretically, we believe that patients will better tolerate the therapy by lowering the dosage of 3-BrOP and combining it with rapamycin."

Other researchers on the study include senior investigator Patrick Zweidler-McKay, M.D., Ph.D., Anna Franklin, M.D. and Wendy Fang, M.D., all from the Children's Cancer Hospital at M. D. Anderson. Peng Huang, M.D., Ph.D., from the Department of Molecular Pathology at M. D. Anderson was also an investigator and was responsible for the development of 3-BrOP.

The team of researchers plans to conduct additional mouse studies, which could lead to a Phase I clinical trial some time in the future.

Source: University of Texas M. D. Anderson Cancer Center

Related stories:

Pittsburgh cancer center warns of cell phone risks
(AP) -- The head of a prominent cancer research institute issued an unprecedented warning to his faculty and staff Wednesday: Limit cell phone use because of the possible risk of cancer.
New approach to cancer: Find most tightly controlled genes
Scientists at a Duke University medical school in Singapore have found a new way to study cancer that could be very useful for developing targeted therapies against cancer and possibly many other diseases.
Multithreaded supercomputer seeks software for data-intensive computing
The newest breed of supercomputers have hardware set up not just for speed, but also to better tackle large networks of seemingly random data. And now, a multi-institutional group of researchers has been awarded $4.0 million to develop software for these supercomputers. Applications include anywhere complex webs of information can be found: from internet security and power grid stability to complex biological networks.
Researchers unveil near-complete protein catalog for mitochondria
Imagine trying to figure out how your car's power train works from just a few of its myriad components: It would be nearly impossible. Scientists have long faced a similar challenge in understanding cells' tiny powerhouses — called "mitochondria" — from scant knowledge of their molecular parts.
Molecular motor works by detecting minute changes in force
Researchers at the University of Pennsylvania School of Medicine discovered that the activity of a specific family of nanometer-sized molecular motors called myosin-I is regulated by force. The motor puts tension on cellular springs that allow vibrations to be detected within the body. This finely tuned regulation has important implications for understanding a wide variety of basic cellular processes, including hearing and balance and glucose uptake in response to insulin. The findings appear in the most recent issue of Science.
New paper offers insights into 'blinking' phenomena
A new paper by a team of researchers led by University of Notre Dame physicist Bolizsár Jankó provides an overview of research into one of the few remaining unsolved problems of quantum mechanics.
Wake up and smell the coffee: Study finds that caffeine may help prevent MS
A good cup of coffee might be just the wake-up call scientists need to stop multiple sclerosis.
Supercomputers join cancer fight
Edmonton-A University of Alberta physicist will lead the fight against cancer, armed with a supercomputer and the will to make Alberta one of the world's top innovation centres.

News discussion:

Medicine & Health news